Governance Cybin Inc.

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-06-16 pm EDT			5-day change	1st Jan Change
8.040 ^USD	-3.71%		-9.66%	-8.84%

Jun. 13	Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	CI
Jun. 13	Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	RE

Executive Committee: Cybin Inc.

Manager

Positions heldSince

Douglas Drysdale

55 year

Chief Executive Officer

2020-07-31

Robert P. Mino

General Counsel

2021-09-30

Allison House-Gecewicz

Chief Tech/Sci/R&D Officer

2022-03-31

Liz Galic

Chief Operating Officer

Naomi Morris

General Counsel

Ryan Richardson

Chief Tech/Sci/R&D Officer

Erica Olson

Comptroller/Controller/Auditor

2021-04-30

Amir Inamdar

Chief Tech/Sci/R&D Officer

2021-09-30

Geoff Varty

Chief Tech/Sci/R&D Officer

2021-09-30

Greg Cavers

55 year

Director of Finance/CFO

2020-11-04

Gabriel Fahel

50 year

Investor Relations Contact	-
Public Communications Contact	-
General Counsel	2020-10-31
Corporate Secretary	2020-10-31

Aaron Bartlone

Chief Operating Officer

2023-06-30

Alex Nivorozhkin

65 year

Chief Tech/Sci/R&D Officer

2020-11-30

Lori Challenger

Chief Administrative Officer	2021-09-30
Compliance Officer	2021-09-30

Eric So

50 year

Founder	2016-10-12
President	2020-11-04

Atul Mahableshwarkar

Chief Tech/Sci/R&D Officer

2024-06-10

Composition of the Board of Directors: Cybin Inc.

Director

CommitteesSince

Eric So

50 year

Compensation Committee	2020-11-04
Governance Committee	2020-11-04
Nominating Committee	2020-11-04

Eric Hoskins

64 year

Audit Committee	2020-11-04
Governance Committee Chair	2023-06-28
Nominating Committee Chair	2023-06-28
Audit Committee Chair	2023-06-28
Compensation Committee Chair	2023-06-28

Mark Lawson

53 year

Audit Committee	2020-06-25
Compensation Committee	2020-11-04
Governance Committee	2020-11-04
Nominating Committee	2020-11-04
Audit Committee Chair	2020-11-04

Theresa Firestone

69 year

Audit Committee	2021-08-15
Compensation Committee Chair	2022-01-03
HR Committee Chair	2022-01-03
Governance Committee	2021-08-15
Nominating Committee	2021-08-15

Paul Glavine

36 year

Audit Committee	2024-08-08
Compensation Committee	2024-08-08
Governance Committee	2024-08-08
Nominating Committee	2024-08-08

George Tziras

44 year

Audit Committee	2021-04-28
Governance Committee	2021-04-28
Nominating Committee	2021-04-28

Grant Froese

63 year

Audit Committee	2020-11-04
Compensation Committee Chair	2020-11-04

Latest Appointments: Cybin Inc.

Cybin Inc. Announces Executive Appointments	24-10-01	CI
Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee	24-08-13	CI
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	24-06-11	CI
Cybin Inc. Announces that George Tziras Joins the Board of Directors and Will Serve as Chief Business Officer	23-10-23	CI
Cybin Appoints Aaron Bartlone as Chief Operating Officer	23-06-30	MT
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023	23-06-29	CI
Cybin Announces Scientific Management Transition	23-06-05	CI

More news

Former Officers and Directors: Cybin Inc.

Insider

Positions held

SinceUntil

Greene Brett

Chief Tech/Sci/R&D Officer

2020-11-30

2023-06-04

Michael Palfreyman

Chief Tech/Sci/R&D Officer

2023-06-04

Leah Gibson

Investor Relations Contact

2021-11-03

2023-05-31

Alexander Belser

Chief Tech/Sci/R&D Officer

2020-09-30

2023-04-30

Joan M. Krakowsky

Chief Tech/Sci/R&D Officer

2023-03-31

Jacqueline Poriadjian-Asch

Investor Relations Contact	-	-
Sales & Marketing	-	2021-12-30

John Kanakis

Founder	2016-10-12	2021-11-03
Investor Relations Contact	2021-03-29	2021-11-03
Public Communications Contact	-	2021-11-03
Corporate Officer/Principal	2021-11-03	2021-11-03

Cameron Carvalho

Corporate Officer/Principal

2021-04-30

Jukka Kalervo Karjalainen

Chief Tech/Sci/R&D Officer

2018-12-31

2021-01-31

Sara Brittany Somerset

Public Communications Contact

Lorenzo Gordon

Corporate Officer/Principal

James Andrews

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	16
Female	6

Of which Executive Committee

Male	11
Female	5

Of which Directors

Male	6
Female	1

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Employees

Sector

Biotechnology & Medical Research

Calendar

Jun. 19 - Psychedelic Science Conference

More about the company